Capital Analysts LLC Cuts Stock Position in Atrion Co. (NASDAQ:ATRI)

Capital Analysts LLC lessened its holdings in Atrion Co. (NASDAQ:ATRI) by 68.5% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 230 shares of the medical instruments supplier’s stock after selling 500 shares during the period. Capital Analysts LLC’s holdings in Atrion were worth $87,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of ATRI. Bank of New York Mellon Corp increased its stake in Atrion by 2.2% in the 1st quarter. Bank of New York Mellon Corp now owns 8,783 shares of the medical instruments supplier’s stock worth $6,263,000 after buying an additional 185 shares in the last quarter. MetLife Investment Management LLC increased its stake in Atrion by 57.0% in the 1st quarter. MetLife Investment Management LLC now owns 777 shares of the medical instruments supplier’s stock worth $554,000 after buying an additional 282 shares in the last quarter. Bridgewater Associates LP increased its stake in Atrion by 28.5% in the 1st quarter. Bridgewater Associates LP now owns 1,985 shares of the medical instruments supplier’s stock worth $1,415,000 after buying an additional 440 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Atrion by 2.6% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 9,988 shares of the medical instruments supplier’s stock worth $7,122,000 after buying an additional 257 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in Atrion by 22.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,913 shares of the medical instruments supplier’s stock worth $1,364,000 after buying an additional 345 shares in the last quarter. Hedge funds and other institutional investors own 66.19% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded Atrion from a “sell” rating to a “hold” rating in a research report on Friday, March 1st.

Atrion Stock Down 3.3 %

Shares of Atrion stock opened at $385.70 on Friday. The firm has a market cap of $678.83 million, a price-to-earnings ratio of 34.97 and a beta of 0.60. The business has a 50-day moving average price of $400.65 and a 200-day moving average price of $365.24. Atrion Co. has a twelve month low of $274.98 and a twelve month high of $670.00.

Atrion (NASDAQ:ATRI) last issued its quarterly earnings data on Thursday, February 29th. The medical instruments supplier reported $3.65 earnings per share for the quarter. The firm had revenue of $43.58 million during the quarter. Atrion had a return on equity of 8.07% and a net margin of 11.46%.

Atrion Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, March 29th. Investors of record on Friday, March 15th were given a $2.20 dividend. The ex-dividend date was Thursday, March 14th. This represents a $8.80 annualized dividend and a yield of 2.28%. Atrion’s dividend payout ratio is currently 79.78%.

Atrion Company Profile

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.